PATRICK HORN: Open Payments
NPI 1841450855 · MOORE, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$366 in 13 payments from 8 companies in 2025. Trend: 2023 $432 · 2024 $584 · 2025 $366
Food & beverage: $268Education: $98
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 2 | $119 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $68 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| Janssen Pharmaceuticals, Inc | 2 | $38 |
| Alkermes, Inc. | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Neurocrine BioSciences, Inc. | 1 | $17 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
Products named: CAPLYTA, INVEGA SUSTENNA, ARISTADA, TRINTELLIX, ABILIFY MAINTENA, UZEDY, REXULTI, INGREZZA.
Industry payments across OK — which companies pay providers there.
